Buying an independent pharmacy with an SBA loan

Published October 25, 2026 · Rules checked against SBA and IRS sources as of October 2026

Short answer

Independent pharmacies are bought with SBA 7(a) loans under the normal acquisition rules: at least 10% equity, a valuation that supports the price, 1.25x historical coverage and a seller exit with up to 24 months of consulting. What's different is the inventory, which can be a large share of the price and counts for little as SBA collateral; reimbursement from insurers and pharmacy benefit managers, which sets margins; and licensing, including a DEA registration that can't be transferred without DEA's written consent.

A pharmacy purchase is a mix of two very different assets: a shelf of drugs that turns over every few weeks, and a stream of prescriptions whose margins are set largely by third-party payers. Lenders underwrite both. This page covers how an SBA 7(a) lender looks at an independent pharmacy acquisition under SOP 50 10 8.1 as of October 2026: the standard rules, the inventory question, reimbursement risk and the licensing timeline. For the buyer's side, see our sister site's guide on how to buy a pharmacy.

The standard rules

Equity: at least 10% of total project cost for an initial acquisition. Up to half of it can come from limited sources such as seller debt on full standby.
Valuation: above a $350,000 Business Purchase Price, an independent valuation from a Qualified Source, ordered by and prepared for the lender.
Coverage: historical cash flow of at least 1.25x the new debt service; projections can be evaluated but not relied on to meet it.
Quality of Earnings: required when the Business Purchase Price is $3 million or more in an initial acquisition or business expansion.
Seller: exits ownership and employment; may consult for up to 24 months.

Inventory: priced separately, counted at closing

Pharmacy inventory is valuable, perishable in the sense that drugs expire, and constantly changing. Most purchase agreements set a price for the business and add inventory at a count taken at or near closing. The method matters: what's counted (saleable, unopened, in-date stock), at what price (acquisition cost from wholesaler invoices is common), and what's excluded (expired, damaged, partial packages, controlled substances handled under their own transfer procedures).

For financing, inventory is a weak collateral asset. SBA's collateral rules require a lien on inventory but count it at only 10% of value. A pharmacy whose price is heavily inventory therefore has a large collateral shortfall, which the lender will look to cover with personal real estate equity where available.

The line pays for the next wholesaler order, not the purchase, unless SBA rules require part of it to.

Worked example

Illustration, not a real deal

Say you're buying a community pharmacy for $850,000 plus inventory counted at closing, estimated at $300,000. Project cost: $1,150,000.

Minimum equity at 10%: $115,000. Term loan: $1,035,000.
Annual payment at an assumed 10% over 10 years: about $164,100.
Adjusted EBITDA after paying a market wage for a pharmacist-in-charge (the seller filled that role): $230,000.
Coverage: $230,000 ÷ $164,100 = 1.40x, above the 1.25x minimum.
Collateral: inventory counts at 10%, so $300,000 of drugs counts as $30,000. Fixtures and equipment count at low percentages too. The shortfall is large, so expect a lien on personal real estate if the owners have equity in it.

If the closing count comes in at $340,000 instead of $300,000, the project grows by $40,000 and so does the equity needed. Agree in advance whether the loan flexes with the count or whether you fund the difference.

The working capital line

Pharmacies buy from wholesalers constantly and get paid by payers on a lag. Many buyers pair the term loan with a revolving line for inventory purchases. One SBA rule to know: if a working capital line takes a first lien on receivables and inventory, 20% to 50% of the line's day-one availability must be used to fund part of the purchase. Plan the structure with the lender before the LOI, not at commitment. See SBA working capital loans.

Reimbursement risk

Most prescription revenue is paid by insurers through pharmacy benefit managers, and the pharmacy's margin on each prescription depends on those contracts, including fees assessed after the claim is paid. Valuers and lenders look past the top line:

Script counts, revenue and gross margin per script, by month for three years, from the dispensing system.
Payer mix by plan type and the trend in margin per script.
Any post-adjudication fees or clawbacks and how they're booked.
Audit history and any recoupments.
Front-store and other services (immunizations, compounding, long-term care) shown separately, with their own margins.

Revenue that a payer could claw back after an audit isn't revenue a lender will rely on. On larger deals, the Quality of Earnings report must assess the sustainability of revenue and margins after the sale.

Licensing and the closing timeline

A pharmacy can't open its doors under a new owner without the right licences in place:

State pharmacy licence for the premises, often issued to the owner and location, with a change-of-ownership process set by the state board.
Pharmacist-in-charge named and licensed in the state.
DEA registration. Federal regulations say a registration may not be assigned or transferred except on conditions DEA sets and only with its written consent. The request goes to DEA with full details of the proposed transfer. Build this into the timeline.
Payer enrollment and contracts, which may need new applications in an asset purchase. A gap means prescriptions filled but not paid.

Lenders will want this sequence mapped out before closing, with a cash cushion for any payment gap.

Closing-day logistics

Pharmacy closings involve steps most businesses don't: an inventory count, often by an independent counting service agreed by both sides; controlled substance records and transfers handled under DEA procedures; transfer of the prescription files and patient records under privacy rules; and changes to wholesaler accounts and credit terms. Wholesalers may want a guarantee or deposit from a new owner, which affects how much working capital you need on day one. Map these out with the seller, your lender and counsel so closing doesn't stall over something administrative.

Valuation points specific to pharmacies

A valuation of a pharmacy separates the business from the inventory and looks at the pieces that make its earnings durable: the prescription file and patient base, location and access, payer contracts, staff and the pharmacist-in-charge, and any specialty or institutional business. Prescriptions tied personally to a seller-pharmacist are a goodwill question, like any professional practice; see medical practice valuations for the parallel issues. For tax, inventory is a Class IV asset allocated at fair market value, which isn't always the wholesaler cost; see inventory in a purchase price allocation.

Who fills the pharmacist role

In many independent pharmacies the owner is also the pharmacist-in-charge and works most of the opening hours. The lender's earnings figure has to include the cost of whoever will do that work after closing. If you are a pharmacist and will work the counter, the lender still tests whether the business supports a reasonable wage for you plus the debt; if you aren't, the cost of a full-time pharmacist-in-charge, and relief cover for other hours, comes off the seller's earnings. In the example above, that adjustment is already in the $230,000. Staffing is also a licensing question, because the pharmacy can't operate without a pharmacist-in-charge named with the state board.

Before you sign the LOI

State board requirements for ownership and change of ownership.
DEA transfer request plan and timing.
Three years of tax returns and dispensing system reports.
Payer and PBM contract list, with transfer or re-enrollment steps.
Inventory count method and price adjustment mechanism.
Lease term and assignment, or the property if you're buying it.
Pharmacist-in-charge and staff plan.

Rules checked against SOP 50 10 8.1 with technical updates (effective October 1, 2026) and 21 CFR 1301.52. This is general information, not legal advice; use healthcare counsel for licensing.

Common questions

Does the buyer have to be a pharmacist?

It depends on the state. Many states require a licensed pharmacist-in-charge at the pharmacy but allow non-pharmacist owners; some have tighter ownership rules. Check with the state board of pharmacy before you make an offer.

How is inventory handled in the price?

Usually separately: a base price for the business plus inventory at a count taken at closing, valued by an agreed method. Because the count changes the final price, agree the method and how it affects the loan amount in the purchase agreement.

Do payer and PBM contracts transfer?

Often not automatically. In an asset purchase the buyer may need new enrollments and contracts, and gaps can delay payments. Lenders want a timeline and a working capital cushion for it.

Does the DEA registration transfer?

Not without DEA's written consent. Federal rules say no registration may be assigned or transferred except on conditions DEA sets and with its written consent, so build the application into the closing timeline.

Related guides

Sources

This guide explains rules and practice in plain English. It isn't legal, tax or credit advice, and SBA and IRS rules change. Check the current SOP, regulations and your lender's requirements before you rely on anything here. Examples with made-up businesses are illustrations, not real deals.